Sara M. Tolaney, MD, MPH
In a video interview, Sara M. Tolaney, MD, MPH, division of breast oncology chief and associate director at Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, discussed:
- how treatments for HER2-positive breast cancer have evolved;
- what it means for a patient to be diagnosed with HER2-low breast cancer and the challenges of treatment;
- the emergence of therapies that are specially tailored to patients with HER2-low breast cancer markers;
- the short- and long-term side effects oncologists should consider when treating patients with HER2-positive breast cancer; and
- barriers to access in breast cancer diagnosis and treatment, and how they can be addressed.
Disclosures: Tolaney reports serving on advisory boards, consulting for, receiving institutional research funds from and/or receving honorarium from 4D Pharm, ARC Therapeutics, Athenex, AstraZeneca, BeyondSpring Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai Pharmaceuticals, Cyclacel, CytomX, Daiichi Sankyo, Eisai, Eli Lilly, Ellipses Pharma, Exelixis, Genentech/Roche, Gilead, Infinity Therapeutics, Merck, Menari/Stemline, Mersana Therapeutics, Myovant, Nanostring, Nektar, Novartis, Odonate, OncoSec Medical Incorporated, OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis and Zymeworks.
Read more about